Acute myeloid dendritic cell leukemia
From Wikipedia, the free encyclopedia
| Acute myeloid dendritic cell leukemia Classification and external resources |
Acute myeloid dendritic cell leukemia is an exceedingly rare form of leukemia. This form of leukemia represents only about 0.8% of all cases of acute myeloid leukemia. Dendritic cells function as antigen-presenting cells. They process antigen material and present it on the surface to other cells of the immune system. Dendritic cells develop from progenitors in the bone marrow and transform into two subtypes: the myeloid dendritic cell and the plasmacytoid dendritic cell. Leukemic transformation can occur in any of these two cells, but transformation of myeloid dendritic cell is much more common and it leads to a form of leukemia known as acute myeloid dendritic cell leukemia.
[edit] Molecular Findings, Cytochemistry, and Molecular Genetics
The WHO criterion for diagnosis of AML is that myeloid precursors or blasts must represent at least 20% of the cellularity of bone marrow. In the case of acute myeloid dendritic cell leukemia, the blast cells are positive for markers of dendritic cells or monocytes. The markers include CD11c, CD80, CD83, CD86, and major histocompatibility complex class II antigens. The neoplastic dendritc cells are negeative for the enzymes myeloperoxidase and esterase. The cells elaborate many cytokines including IL-6 and IL-12.
[edit] Clinical Findings
Anemia, thrombocytopenia, and blood, marrow, and skin involvement with dendritic-like blast and more mature appearing dendritic cells are characteristic findings. Lymph node and spleen enlargement from leukemic cell infiltration usually is present.
[edit] References
[1] Lichtman MA and Segel GB: Uncommon phenotypes of acute myelogenous leukemia: basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: a review.; Blood Cells Mol Dis. 2005 Nov-Dec;35(3):370-83.
[2] A. Orfao, Neoplasias of dendritic cells: are they the counterparts of one or more cell lineages, Lab. Hematol. 10 (2004) 171.
[3] C. Bueno, J. Almeida, P. Lucio, J. Marco, R. Garcia, J.M. de Pablos, et al., Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies, Haematologica 89 (2004) 58– 69.
[4] M. Klammer, M.Waterfall, K. Samuel, M.L. Turner, P.H. Roddie, Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia, Br. J. Haematol. 129 (2005) 340–349.
[5] F. Re, M. Arpinati, N. Testoni, P. Ricci, C. Terragna, P. Preda, et al., Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage, Exp. Hematol. 30 (2002) 126–134.
[6] F. Gomis, F. Moscardo, F. Mayordormo, G. Martin, A. Sempere, M.A. Sanz, Bone marrow infiltrate by atypical histiocytic cells with cytoplasmic Birbeck granules as initial presentation of an acute monoblastic leukemia, Haematologia 86 (2001) 879– 880.
[7] S.-I. Fujii, K. Shimizu, F. Koji, F. Kawano, Malignant counterpart of myeloid dendritic cell (CD) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential, J. Leukocyte Biol. 73 (2003) 82– 90.
|
||||||||||||||||||||||||||||||||||||
